A review of inflammatory bowel disease from the perspective of Persian medicine

被引:0
|
作者
Hasheminasab, Fatemeh sadat [1 ,2 ]
Azimi, Maryam [3 ,4 ]
机构
[1] Zahedan Univ Med Sci, Pharmacol Res Ctr, Zahedan, Iran
[2] Zahedan Univ Med Sci, Sch Med, Dept Genet, Zahedan, Iran
[3] Kerman Univ Med Sci, Gastroenterol & Hepatol Res Ctr, Kerman, Iran
[4] Kerman Univ Med Sci, Sch Persian Med, Dept Tradit Med, Kerman, Iran
关键词
Inflammatory bowel disease; Persian medicine; Medical history; Avicenna; Iran; Traditional medicine; IRANIAN TRADITIONAL MEDICINE; ULCERATIVE-COLITIS; CHINESE MEDICINE; SPLENIC FUNCTION; DOUBLE-BLIND; EFFICACY; DIFFERENTIATION; PARAMETERS; SYSTEMS; TRIAL;
D O I
10.1016/j.explore.2024.103041
中图分类号
R [医药、卫生];
学科分类号
10 ;
摘要
The initial descriptions of inflammatory bowel disease (IBD) have been a topic of discussion. Cases of persistent diarrhea have been documented as far back as ancient Greece, with even Hippocrates (similar to 460-370 BCE) exploring various potential causes of diarrhea. Persian medicine was the predominant medical practice in the Eurasia region until the 18th century and had roots in Hippocrates and the ancient civilization of the region. Scholars, such as Avicenna (980-1025 CE), extensively described a disease characterized by intestinal ulcers, bloody diarrhea, and abdominal pain in the early medieval period. While some of the definitions and etiologies of IBD in Persian medicine are based on humoral theories that differ from current medical concepts, recent studies have suggested a potential relationship between the traditional Persian medicine understanding of the disease and IBD. Persian medicine classifies patients with specific diseases into different types of disorders known as dystemperament, with the application of these differences referred to as "syndrome differentiation." These traditional classifications require distinct therapeutic approaches. Research has delved into the molecular bases of the humoral theory and the impact of syndrome differentiation on drug selection for patients, including those with IBD. However, further research is needed to explore the potential effectiveness of Persian medicine in treating IBD and to understand how this ancient classification system can contribute to improved disease management.
引用
收藏
页数:5
相关论文
共 50 条
  • [21] Inflammatory Bowel Disease and Pancreatitis: A Review
    Ramos, Lidia Roque
    Sachar, David B.
    DiMaio, Christopher J.
    Colombel, Jean-Frederic
    Torres, Joana
    JOURNAL OF CROHNS & COLITIS, 2016, 10 (01) : 95 - 104
  • [22] Flavonoids in Inflammatory Bowel Disease: A Review
    Vezza, Teresa
    Rodriguez-Nogales, Alba
    Algieri, Francesca
    Pilar Utrilla, Maria
    Elena Rodriguez-Cabezas, Maria
    Galvez, Julio
    NUTRIENTS, 2016, 8 (04):
  • [23] Nutrition in Pediatric Inflammatory Bowel Disease: From Etiology to Treatment. A Systematic Review
    Penagini, Francesca
    Dilillo, Dario
    Borsani, Barbara
    Cococcioni, Lucia
    Galli, Erica
    Bedogni, Giorgio
    Zuin, Giovanna
    Zuccotti, Gian Vincenzo
    NUTRIENTS, 2016, 8 (06):
  • [24] Budesonide in the treatment of inflammatory bowel disease
    Silverman, Jason
    Otley, Anthony
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2011, 7 (04) : 419 - 428
  • [25] Regenerative medicine: prospects for the treatment of inflammatory bowel disease
    Almeida-Porada, Graca
    Soland, Melisa
    Boura, Joana
    Porada, Christopher D.
    REGENERATIVE MEDICINE, 2013, 8 (05) : 631 - 644
  • [26] Development and Application of Regenerative Medicine in Inflammatory Bowel Disease
    Okamoto, Ryuichi
    Mizutani, Tomohiro
    Shimizu, Hiromichi
    DIGESTION, 2023, 104 (01) : 24 - 29
  • [27] Treatments of inflammatory bowel disease toward personalized medicine
    Kim, Ki-Uk
    Kim, Jisu
    Kim, Wan-Hoon
    Min, Hyeyoung
    Choi, Chang Hwan
    ARCHIVES OF PHARMACAL RESEARCH, 2021, 44 (03) : 293 - 309
  • [28] Treatments of inflammatory bowel disease toward personalized medicine
    Ki-Uk Kim
    Jisu Kim
    Wan-Hoon Kim
    Hyeyoung Min
    Chang Hwan Choi
    Archives of Pharmacal Research, 2021, 44 : 293 - 309
  • [29] Switching from an originator anti-TNF to a biosimilar in patients with inflammatory bowel disease: Can it be recommended? A systematic review
    Gisbert, Javier P.
    Chaparro, Maria
    GASTROENTEROLOGIA Y HEPATOLOGIA, 2018, 41 (06): : 389 - 405
  • [30] Pregnancy and medications for inflammatory bowel disease: An updated narrative review
    Akiyama, Shintaro
    Steinberg, Joshua M.
    Kobayashi, Mariko
    Suzuki, Hideo
    Tsuchiya, Kiichiro
    WORLD JOURNAL OF CLINICAL CASES, 2023, 11 (08) : 1730 - 1740